PAI-1 as a target in kidney disease.

PAI-1 as a target in kidney disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

PAI-1 as a target in kidney disease. Abstract Text:

Yufeng Huang,Nancy A Noble,

Fibrotic renal diseases represent a major health care problem because of their prevalence and the fact that available therapies merely slow, but do not halt progression to renal failure. New therapies to further slow or stop the progression to end stage of renal disease (ESRD) are urgently needed. PAI-1 has emerged as a powerful fibrogenic molecule in kidney disease and its overexpression has effects beyond its role in regulating the fibrinolytic system. PAI-1's ability to inhibit plasmin-dependent extracellular matrix turnover, to stimulate infiltration of macrophages and myofibroblasts and to signal directly to regulate transforming growth factor-beta 1 expression, provide possible mechanistic pathways involved in progression of chronic kidney disease. Blockade of PAI-1 represents a new and promising therapeutic approach that may help combat the current epidemic in chronic kidney disease.

PAI-1 as a target in kidney disease. Publishing Authors By Initials

Y Huang,NA Noble,

For similar peptides: intercellular signaling peptides and proteins: cytokines: transforming growth factor beta research abstracts see: peptides: intercellular signaling peptides and proteins: cytokines: transforming growth factor beta research

PUBMED ID PMID:

MEDLINE DATE:

PAI-1 as a target in kidney disease. Journal Published:

PUBLICATION TYPE: Review

Journal: Current drug targets

VOLUME: 8

Page Numbers: 1007-15

Journal Abbreviation:

ISSN: 1873-5592

DAY: 3

MONTH: Sep

YEAR: 2007

PAI-1 as a target in kidney disease. Information

Number of References: 121

LANGUAGE: eng

NlmUniqueID: 100960531

PAI-1 as a target in kidney disease. Keywords Mesh Terms:

KEYWORDS: Transforming Growth Factor beta

MESH TERMS: metabolism

Chemical & Substance for Abstract: PAI-1 as a target in kidney disease. Information

Substance Name: Transforming Growth Factor beta

Registry Number: 0

Grant and Affiliation Information for PAI-1 as a target in kidney disease.

AFFILIATION: Fibrosis Research Laboratory, Division of Nephrology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84108, USA.

Country: Netherlands

AGENCY: United States NIDDK

GRANT: DK60508

ACRONYM: DK

MEDLINETA: Curr Drug Targets

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

PAI-1 as a target in kidney disease Related Publications

• A field study of the fertility of transported equine semen.
• A structural alignment kernel for protein structures.
• Benefits of sign language interpreting and text alternatives for deaf students' classroom learning.
• Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
• CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo.
• Chemically diverse toxicants converge on Fyn and c-Cbl to disrupt precursor cell function.
• Comment on "Discrimination of shifts in a soil microbial community associated with TNT-contamination using a functional ANOVA of 16S rRNA hybridized to oligonucleotide microarrays".
• Detection of estrus with cows administered testosterone via injections and/or silastic implants.
• Development of a statistically robust quantification method for microorganisms in mixtures using oligonucleotide microarrays.
• Does external evaluation of laboratories improve patient safety?
• Ethics in the trenches: a multifaceted analysis of the stem cell debate.
• High variability in melting profiles from gel pad arrays.
• Hyaluronan in tissue injury and repair.
• Long term effects of early nutritional support with new enterotropic peptide-based formula vs. standard enteral formula in HIV-infected patients: randomised prospective trial Chlebowski R T, Beall G, Grovenor M, Lillington L, Weintraub N, Ambler C, Richar
• Modeling cardiac ischemia.
• Mutations of the betaN102 residue of HbA not only inhibit the ligand-linked T to Re state transition, but also profoundly affect the properties of the T state itself.
• Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis.
• Oligonucleotide microarrays: widely applied--poorly understood.
• PAI-1 as a target in kidney disease.
• Revision of the nonequilibrium thermal dissociation and stringent washing approaches for identification of mixed nucleic acid targets by microarrays.
• Speech perception and localization with adults with bilateral sequential cochlear implants.
• Support vector machine learning from heterogeneous data: an empirical analysis using protein sequence and structure.
• The evidence base of palliative medicine: is inpatient palliative medicine evidence-based?
• The genetic transmission of alcoholism: implications for prevention.
• The maturation of rat brain myelin.
• The role of Toll-like receptors in non-infectious lung injury.
• The role of growth factors and related agents in accelerating fracture healing.
• Unsupervised segmentation of continuous genomic data.
• Use of forensic DNA evidence in prosecutors'offices.
• [Constituents of the essential oil of myrrh.]